Search Results 471-480 of 18880 for Neutrophil

1. Bemarituzumab plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone - Mayo Clinic

   - Absolute neutrophil count ≥ 1.5 x 10^9/L - Platelet count ≥ 100 x 10^9/L - Hemoglobin ≥ 9 g/dL without red blood cell (RBC) transfusion within 7 days ...

2. A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies - Mayo Clinic

   ... neutrophil count ≥ 1.5 × 10^9 /L, platelet count ≥ 75 × 10^9/L, hemoglobin ≥ 80 g/L; if presence of bone marrow infiltration, neutrophil count ≥ 1.0 ...

3. Clinical trials - Oncology (Medical)

   MC1733, Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori Neutrophil-activating Protein (NAP) ...

4. Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients with Myelofibrosis - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1000/uL; Platelet count ≥ 50,000/uL; Serum creatinine ≤ 1.5 x the upper limit of normal (ULN); Total bilirubin ≤ 1.5 x ...

5. Publications - Erica A. Loomis, M.D. - Mayo Clinic

   Neutrophil Extracellular Trap Formation and Syndecan-1 Shedding Are Increased After Trauma. Shock. 2021 Sep 1; 56 (3):433-439. View PubMed; Ferrara MJ ...

6. Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1500/uL; Platelets (PLT) ≥ 100,000/uL; Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate aminotransferase ...

7. Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia - Mayo Clinic

   Absolute neutrophil count (ANC) ≥ 1000/mm³;; Platelet count ≥ 75,000/mm³;. NOTE: platelet transfusions in order to help patients meet eligibility criteria ...

8. Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer - Mayo Clinic

   ECOG Performance Status 0-2. Required Initial Laboratory Values: Absolute Neutrophil Count (ANC). ≥ 1,500/mm^3. Platelet Count. ≥ 100,000/mm^3. Calc ...

9. A Study To Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC - Mayo Clinic

   Participation eligibility · Absolute neutrophil count (ANC) ≥ 1.5 x 10^9 /L; · Platelets ≥ 100 x 10^9 /L; · Hemoglobin (Hgb) > 9 g/dL; · Creatinine clearance ...

10. Clinical trials - Oncology (Medical)

    MC1733, Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori Neutrophil-activating Protein (NAP) ...